MeSH term
Frequency | Condition_Probility | Animals | 54 | 0.0 |
Base Sequence | 41 | 0.0 |
*DNA-Binding Proteins | 38 | 2.0 |
Exons | 2 | 0.0 |
Female | 16 | 0.0 |
Genes, Reporter | 7 | 0.0 |
Humans | 84 | 0.0 |
Introns | 2 | 0.0 |
Molecular Sequence Data | 38 | 0.0 |
Pregnancy | 4 | 0.0 |
*Promoter Regions (Genetics) | 11 | 0.0 |
*Repressor Proteins | 45 | 3.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 44 | 0.0 |
Trans-Activation (Genetics) | 11 | 0.0 |
*Transcription Factors | 40 | 2.0 |
Transfection | 19 | 0.0 |
Tumor Cells, Cultured | 15 | 0.0 |
Cell Cycle | 2 | 0.0 |
Cell Division | 3 | 0.0 |
Cell Line, Tumor | 4 | 0.0 |
Down-Regulation | 3 | 0.0 |
Gene Expression Regulation | 7 | 0.0 |
Male | 14 | 0.0 |
Research Support, Non-U.S. Gov't | 65 | 0.0 |
Binding Sites | 17 | 0.0 |
Cells, Cultured | 15 | 0.0 |
DNA/metabolism | 4 | 0.0 |
*Transcription, Genetic | 6 | 0.0 |
Blotting, Southern | 4 | 0.0 |
Cell Adhesion | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
*Chromosome Mapping | 4 | 0.0 |
Chromosomes, Human, Pair 21 | 4 | 3.0 |
Genotype | 2 | 0.0 |
In Situ Hybridization, Fluorescence | 4 | 0.0 |
Karyotyping | 4 | 0.0 |
Phenotype | 5 | 0.0 |
3T3 Cells | 8 | 0.0 |
Mice | 39 | 0.0 |
Promoter Regions (Genetics)/genetics | 2 | 0.0 |
Protein Binding | 7 | 0.0 |
Proto-Oncogene Proteins/*genetics/metabolism | 5 | 3.0 |
Rats | 2 | 0.0 |
*Trans-Activation (Genetics) | 4 | 0.0 |
Trans-Activators/*genetics/metabolism | 2 | 1.0 |
Apoptosis/*physiology | 2 | 0.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Cell Line | 17 | 0.0 |
Cell Survival/physiology | 3 | 1.0 |
Proto-Oncogene Proteins/*physiology | 6 | 2.0 |
Trans-Activators/*physiology | 4 | 1.0 |
Blotting, Western | 5 | 0.0 |
Cloning, Molecular | 8 | 0.0 |
Comparative Study | 12 | 0.0 |
Mutagenesis, Site-Directed | 3 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 7 | 0.0 |
Sequence Homology, Nucleic Acid | 8 | 0.0 |
Transcription, Genetic/genetics | 2 | 0.0 |
DNA-Binding Proteins/*physiology | 4 | 0.0 |
Fibroblasts | 3 | 0.0 |
*Gene Expression Regulation | 8 | 0.0 |
*MAP Kinase Kinase Kinase 1 | 2 | 1.0 |
MAP Kinase Signaling System | 2 | 0.0 |
Promoter Regions (Genetics) | 14 | 0.0 |
Transcription Factors/*physiology | 3 | 0.0 |
Down Syndrome/genetics | 3 | 11.0 |
Gene Dosage | 3 | 0.0 |
Mice, Transgenic | 9 | 0.0 |
*Multigene Family | 5 | 0.0 |
Trisomy | 3 | 2.0 |
Cell Differentiation/genetics | 2 | 0.0 |
Gene Deletion | 2 | 0.0 |
Gene Expression Regulation, Developmental | 4 | 0.0 |
Gene Targeting | 4 | 1.0 |
Mice, Inbred C57BL | 5 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Cell Division/physiology | 2 | 0.0 |
*Cell Transformation, Neoplastic | 5 | 1.0 |
Gene Expression Regulation, Neoplastic | 5 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Proto-Oncogene Proteins/biosynthesis/genetics/*physiology | 2 | 8.0 |
Trans-Activators/biosynthesis/genetics/*physiology | 2 | 13.0 |
*Tumor Suppressor Proteins | 2 | 0.0 |
Mice, Knockout | 3 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 9 | 0.0 |
Signal Transduction | 6 | 0.0 |
Transcription Factors/*metabolism | 12 | 0.0 |
Cell Nucleus/metabolism | 3 | 0.0 |
Cytoplasm/metabolism | 2 | 0.0 |
Electrophoresis | 2 | 0.0 |
Kinetics | 2 | 0.0 |
Plasmids/metabolism | 3 | 0.0 |
Transcription, Genetic | 10 | 0.0 |
DNA-Binding Proteins/metabolism | 8 | 0.0 |
Proto-Oncogene Proteins/genetics/*metabolism | 5 | 1.0 |
Trans-Activators/genetics/*metabolism | 4 | 1.0 |
Transcription Factors/metabolism | 2 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
Trans-Activation (Genetics)/physiology | 2 | 2.0 |
Binding Sites/genetics | 4 | 0.0 |
DNA/genetics/metabolism | 2 | 0.0 |
Adult | 6 | 0.0 |
Chromosome Mapping | 10 | 0.0 |
*Chromosomes, Human, Pair 21 | 12 | 7.0 |
DNA Primers | 5 | 0.0 |
Down Syndrome/*genetics/metabolism | 2 | 25.0 |
Middle Aged | 3 | 0.0 |
Proto-Oncogene Proteins/*genetics | 13 | 1.0 |
Reference Values | 3 | 0.0 |
Trans-Activators/*genetics | 7 | 2.0 |
Cell Differentiation | 2 | 0.0 |
DNA | 2 | 0.0 |
Trans-Activators/metabolism | 2 | 0.0 |
COS Cells | 2 | 0.0 |
Chloramphenicol O-Acetyltransferase/genetics | 2 | 0.0 |
DNA, Complementary | 2 | 0.0 |
Proto-Oncogene Proteins/genetics/*physiology | 2 | 2.0 |
Oncogenes | 2 | 0.0 |
Stromelysin 1/genetics | 2 | 11.0 |
Immunohistochemistry | 3 | 0.0 |
DNA-Binding Proteins/*metabolism | 4 | 0.0 |
Ionomycin/pharmacology | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Trans-Activators/*metabolism | 4 | 0.0 |
Phosphorylation | 4 | 0.0 |
Up-Regulation | 2 | 0.0 |
Transcription Factors/*genetics/metabolism | 3 | 0.0 |
Blotting, Northern | 5 | 0.0 |
*Gene Expression Regulation, Neoplastic | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Sequence Deletion | 2 | 0.0 |
Chromosomes, Human, Pair 21/*genetics | 4 | 4.0 |
Down Syndrome/*genetics | 9 | 12.0 |
Genetic Markers | 5 | 0.0 |
Chromosome Banding | 3 | 0.0 |
*Trans-Activators | 9 | 1.0 |
*Mutation | 3 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
DNA/*metabolism | 2 | 0.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Polymerase Chain Reaction | 7 | 0.0 |
Transcription Factors/*genetics | 3 | 0.0 |
Chromosomes, Artificial, Yeast | 2 | 0.0 |
Transcription Factor AP-1/metabolism | 2 | 0.0 |
Cell Line, Transformed | 5 | 0.0 |
RNA, Messenger/metabolism | 2 | 0.0 |
Mutation | 4 | 0.0 |
*Regulatory Sequences, Nucleic Acid | 2 | 0.0 |
ras Proteins/*metabolism | 2 | 1.0 |
Carcinoma, Squamous Cell/*genetics/pathology | 2 | 3.0 |
*Chromosome Aberrations | 2 | 0.0 |
Mice, Nude | 3 | 0.0 |
Proto-Oncogenes | 2 | 1.0 |
Transplantation, Heterologous | 2 | 0.0 |
Gene Expression | 2 | 0.0 |
*Proto-Oncogenes | 13 | 1.0 |
RNA, Messenger/genetics | 5 | 0.0 |
Hela Cells | 4 | 0.0 |
Proto-Oncogene Proteins c-myb | 2 | 3.0 |
Multigene Family | 5 | 0.0 |
Cell Nucleus/physiology | 3 | 4.0 |
Enzyme Activation | 4 | 0.0 |
Retroviridae Proteins, Oncogenic/*genetics/physiology | 2 | 66.0 |
Chromosomes, Human, Pair 21/*ultrastructure | 2 | 33.0 |
DNA Probes | 3 | 0.0 |
DNA, Complementary/genetics | 2 | 0.0 |
*Translocation, Genetic | 2 | 0.0 |
DNA/genetics | 3 | 0.0 |
Species Specificity | 2 | 0.0 |
Gene Expression Regulation/genetics | 2 | 1.0 |
Polymorphism, Restriction Fragment Length | 4 | 0.0 |
Evolution | 2 | 0.0 |
Protein-Tyrosine Kinase/genetics | 5 | 4.0 |
Human T-lymphotropic virus 1/*genetics | 2 | 3.0 |
Recombinant Proteins/metabolism | 2 | 0.0 |
*Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Binding, Competitive | 2 | 0.0 |
Oligonucleotide Array Sequence Analysis | 2 | 0.0 |
Oligonucleotide Probes | 2 | 0.0 |
*Oncogenes | 3 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Chromosome Deletion | 2 | 0.0 |
Alleles | 3 | 0.0 |
Transcription Factor, Sp1/metabolism | 3 | 0.0 |
Protein Kinase C/*metabolism | 3 | 1.0 |
Child | 2 | 0.0 |
DNA/genetics/isolation & purification | 2 | 0.0 |
Gene Expression Regulation, Neoplastic/genetics | 2 | 1.0 |
Protein Structure, Tertiary/genetics | 2 | 0.0 |
Alzheimer Disease/*genetics | 3 | 0.0 |
Membrane Proteins/*genetics | 2 | 0.0 |
Breast Neoplasms/genetics/*metabolism | 2 | 3.0 |
Gene Expression Regulation, Neoplastic/physiology | 2 | 1.0 |
Proto-Oncogene Proteins/biosynthesis/*genetics | 2 | 3.0 |
Trans-Activators/biosynthesis/*genetics | 2 | 9.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
